How has been the historical performance of Panacea Biotec?

Answer:The historical performance of Panacea Biotec shows fluctuations in net sales, operating profit, and net profit over the years, with a notable decline in profitability in recent periods. Breakdown: Panacea Biotec's net sales have remained relatively stable, with figures of 559.09 crore in March 2025, slightly down from 559.17 crore in March 2024, but significantly higher than 459.95 crore in March 2023. The total operating income followed a similar trend, peaking at 661.23 crore in March 2022 before declining to 559.09 crore in March 2025. Operating profit (PBDIT) has been negative in recent years, reaching -25.91 crore in March 2025, compared to -20.06 crore in March 2024 and -97.96 crore in March 2023. The profit before tax also turned negative at -7.95 crore in March 2025, down from a positive 1.48 crore in March 2024. Consequently, the profit after tax showed a loss of -8.72 crore in March 2025, compared to -1.50 crore in March 2024 and a loss of -33.75 crore in March 2023. The company's total assets increased to 1,289.75 crore in March 2025 from 1,240.82 crore in March 2024, while total liabilities also rose to 1,289.75 crore in March 2025. Cash flow from operating activities remained negative at -27.00 crore in March 2025, although the net cash inflow was positive at 34.00 crore. Overall, the financial performance indicates challenges in profitability despite stable sales figures.